MCAS Article 1: MCAS and ME/CFS: Why Your Body Reacts to Nothing
It’s 4 p.m. again. Your face flushes, your nose runs, your throat feels tight — same time as yesterday, same time as last Tuesday. There’s no pollen. You ate nothing new. You didn’t change detergent. There’s no cat in the room. Your body is having an allergic reaction to nothing.
Now add the rest of ME/CFS: the crashing fatigue, the brain fog, the unrefreshing sleep. Somewhere in the middle of it, your doctor or your online support group says the word MCAS and hands you an antihistamine and tells you to “just try it.”
This article is the conceptual overview. What MCAS actually is, how mast cells can fire with no allergen involved, whether MCAS causes ME/CFS (it almost never does), and the difference between having MCAS on its own and having it on top of ME/CFS. The treatments — the H1 and H2 antihistamines, dosing, and stabilisers — are covered in the companion treatment article, and the honest “what if the drugs don’t work” discussion in the companion article on treatment failure.
1 First, a plain warning
This is an explanation, not self-medication advice, and I am not a doctor. If your symptoms feel sudden, severe, or life-threatening — especially any breathing difficulty or swelling in the throat — that is an emergency. Go to a hospital. Everything below is medicine you will likely be offered; talk to a prescriber before starting, stopping, or changing any of it.
2 The short version, if you only read one part
- MCAS stands for mast cell activation syndrome. Mast cells are immune cells that fire off chemical signals. In MCAS they fire too easily, at the wrong moments, and in the wrong amounts (Valent et al. 2021).
- Histamine is the most famous of those signals. It is not the only one, but it is the one antihistamines target.
- MCAS is genuinely more common in ME/CFS than in the general population, and a meaningful subset report improvement with mast-cell–targeted treatment — though the evidence for that improvement is uncontrolled and the criteria themselves are contested (Rohrhofer et al. 2025).
- But for almost everyone, MCAS was detected after ME/CFS began. Whether it’s then an amplifier that worsens the illness, or largely a bystander that just co-exists, is not yet settled — so keep neither “hidden cause” nor “definitely worth treating” as a certainty.
- There is a useful (if imperfect) distinction between MCAS on its own and ME/CFS-with-MCAS. Treating mast cells in the first is treating the primary condition; in the second it’s treating one possible contributor among several.
3 What is a mast cell, for real?
Mast cells are immune cells that live all over your body — inside your skin, your nose, your lungs, your gut, and near your blood vessels and your nerves. They are one of the first responders of the immune system. When triggered, they burst open and release a cocktail of ready-made chemicals. The classic fuse is an allergen binding to an antibody. But mast cells also listen to stress hormones, to nerve signals, and to fragments of infection (Elieh Ali Komi et al. 2020).
The chemicals they release include histamine, prostaglandins, leukotrienes, tryptase, and dozens more. Each does its own job: widening blood vessels, making tissue swell, recruiting other immune cells, irritating nerve endings.
In a healthy person, this is a targeted, quickly-put-out fire. An allergen meets a mast cell, the mast cell fires, and the reaction is brief and localised. In MCAS, the fire alarm is stuck. Cells discharge with too small a trigger or no clear trigger at all (Molderings et al. 2011).
Here is the sentence that matters for ME/CFS: mast cells sit right next to nerve endings, blood vessels, and microglia — the brain’s own immune cells. In animal and cell models this places them where a flare could influence circulation, nerve signalling, and neuroinflammation — but most of that wiring is documented in other contexts, and whether it operates in ME/CFS patients has not been directly shown (Theoharides, Twahir, and Kempuraj 2024). Treat the “mast cells near nerves/vessels” geography as a plausible route, not a demonstrated one; and be aware that much of this neuro-mast-cell model comes from a small group of researchers, so independent replication is thin.
4 Wait — an allergic reaction without an allergen? How does that happen?
A lot of people think “allergic reaction” requires an allergen. That is the allergy you already know — the classic IgE pathway. In ME/CFS, an idea widely believed but not yet proven in a cohort is that the non-allergen pathways matter more than the classic one — they can bypass allergens entirely, and they fit the “no obvious trigger” pattern (Roy et al. 2021). (The evidence that these pathways exist is solid; the comparative claim that they dominate in ME/CFS has not been directly measured.)
Mast cells have other triggers built in:
- Stress hormones. Corticotropin-releasing hormone (CRH), released when you’re stressed, can directly activate mast cells, including ones in the hypothalamus (Theoharides, Twahir, and Kempuraj 2024). Don’t over-read this a step further: it shows a stress→mast-cell link exists at the cellular level; it does not show that this chain is what drives sleep or energy symptoms in ME/CFS patients.
- Nerve signals. The neuropeptide substance P — released by sensory nerves — can degranulate mast cells through a receptor called MRGPRX2, with no antibody involved at all (Thapaliya et al. 2022).
- Complement fragments. Parts of the immune-complement system, which attack invaders, can also set mast cells off (Elieh Ali Komi et al. 2020).
This is one possible reading of the 4 p.m. flush with no pollen: that the trigger isn’t a visible allergen from outside but an internal, neuro-immune signal — which can in some cases follow a daily rhythm (Weinstock, Nelson, and Blitshteyn 2023). Keep the honest alternative in view: an unnoticed chronic allergen (and dust mite is everywhere) could produce the same pattern, so the “no allergen” interpretation is a hypothesis for a given person, not a certainty.
5 The MCAS–ME/CFS overlap, in numbers
Before you pin your hopes on it, here is what the data actually says.
A two-cohort study of over a thousand ME/CFS patients (from a specialty-referral setting) found about 1 in 6 met criteria for full MCAS after their illness began, and about 1 in 4 met the broader criteria for mast cell activation (Rohrhofer et al. 2025). Those numbers exceed the general population — though not necessarily like-for-like, since comparison figures swing hugely with the criteria used and these patients were screened intensively in a specialist clinic, so the “above general population” gap is suggestive of enrichment rather than a clean measurement. Patients who had both ME/CFS and MCAS were more likely to have orthostatic intolerance — the blood-pressure and heart-rate instability linked to POTS — than ME/CFS patients without MCAS (Rohrhofer et al. 2025).
Read the prevalence numbers with a critical caveat. MCAS diagnostic criteria are themselves contested: the international consensus criteria (Valent/Akin/Weiler) are deliberately strict — they require a mediator elevation during a flare plus a treatment response (Valent et al. 2021) — while the broader clinician framework (Afrin/Molderings) diagnoses far more people, and estimates in the literature swing from roughly 2% to over 80% depending on which definition you use. Some allergy specialists argue that much broadly-diagnosed “MCAS” is relabelled dysautonomia, IBS, or anxiety. So “MCAS is common in ME/CFS” is only as strong as the criteria behind the study, and the numbers above come from one research group using one criteria set in one referral population — a useful signal, not a fixed prevalence.
The overlap has a plausible chemistry: mast cells produce mediators (including histamine and prostaglandin D₂) that dilate blood vessels and drop blood pressure — the wrong chemistry for a nervous system already struggling to keep blood flowing to the brain (Kohno et al. 2021). That chemistry is consistent with the POTS / hypermobility / MCAS cluster appearing together, but it doesn’t prove the chemistry causes the cluster — hypermobility, for instance, could drive all three (Yao et al. 2025).
So the honest position: MCAS is real in ME/CFS, it is more common than in the general public, and it is likely one contributor to symptoms in the subset of people who have it — not the single cause of ME/CFS for everyone (Castells et al. 2024).
6 The order matters: MCAS is usually downstream, not the cause
Here is a fact that should shape how you think about everything that follows: most people with ME/CFS develop mast cell trouble after their illness begins, not before it. In the large two-cohort study, roughly 97% of ME/CFS patients who had MCAS developed it only after ME/CFS was already established (Rohrhofer et al. 2025). Fair caveats apply before anyone builds too much on it: this is when MCAS was detected, not necessarily when it biologically began — people are screened for MCAS after ME/CFS brings them into specialist care, and onset-ordering is self-reported and years in the past, so it is vulnerable to recall and detection-order effects. Treat it as suggestive of a downstream relationship, not a settled biological fact, and it needs replication.
Before we read too much into that: Mast cells can feed back and amplify an illness, so “it started after” does not mean “it doesn’t matter.” The relationship is best seen as a possible two-way loop: the initial fuel for ME/CFS comes from elsewhere, and mast cell activation rides on top of it, plausibly adding flushing, histamine symptoms, and nerve irritation that make the whole picture worse (WirthLohn 2023). Whether interrupting that loop meaningfully eases the ME/CFS course is a reasonable hope, but an untested prediction — the hostile data (an old negative antihistamine RCT in chronic fatigue, and a negative ketotifen trial in fibromyalgia) are exactly what a weaker “bystander” reading would predict. So: treat it, yes, but don’t let an article’s enthusiasm overstate what is, right now, an open question.
But this temporal fact does two important, honest things:
- It cools down the “MCAS is the hidden cause of ME/CFS” story. A condition detected in 97% of affected people after the disease it supposedly causes is unlikely to be the original spark for most of them — though, given the detection-order limits above, this weakens rather than kills the possibility. Two honest readings remain on the table: MCAS could be a later amplifier that worsens the existing illness, or it could be a largely bystander/epiphenomenon that simply accumulates because it’s measured in a sicker, longer-ill group. The data we currently have do not cleanly separate these two — the “amplifier” reading is a reasonable model, not a proven fact. Note what would and wouldn’t discriminate: an individual treatment response can’t (a placebo, or mere relief of the mast-cell symptoms themselves, would look identical), and neither would a trial showing benefit on mast-cell symptoms alone — because a bystander’s own symptoms also improve. Only a controlled trial that shows the treatment improves core ME/CFS outcomes (PEM, fatigue, function) beyond those mast-cell symptoms would move the amplifier reading above the bystander one; such a trial has not been done (Castells et al. 2024).
- It changes how you should read a treatment success or failure — with an honest limit. If an antihistamine helps you, a tempered reading is: histamine signalling was contributing to your symptoms — from mast cells or from elsewhere (drugs can block histamine that isn’t pathologically elevated). It does not by itself prove mast cells were driving you, and it does not mean the underlying energy/immune problem is fixed. You can win the histamine fight and still have ME/CFS. Treating “response = amplifier proven” too strongly would be the same mistake the article warns against elsewhere (Loth 2026).
Think of a machine that overheats. The room getting hotter is not why the machine was faulty, but cooling the room is still worth doing. You are not treating the machine’s core defect by turning on the fan — you are stopping one feedback loop that makes the overheating worse.
7 MCAS by itself vs ME/CFS with MCAS
A lot of the confusion around MCAS comes from mixing up two situations that often differ but don’t have a clean biological border. They look similar — the same flush, the same hives, the same gut pain — but the treatment goal and the meaning of a failure can be different. Treat this as a useful clinical distinction, not a hard diagnostic fact: because ME/CFS is defined by a symptom pattern, a person whose MCAS is severe enough can technically meet ME/CFS criteria on the same presentation — so the boundary is diagnostic and judgement-dependent, not a biological wall.
MCAS on its own (no ME/CFS). In someone who doesn’t have ME/CFS, MCAS is the dominant complaint. The flushing, urticaria, swelling, cramping, and episodic reactions are the disease being treated. Mast cells are the thing to fix, and treating them is treating the primary condition. If the symptoms respond, you’ve blocked the mediator producing those symptoms — which is the goal itself, though even here a response to a receptor blocker is evidence that histamine signalling was contributing, not independent proof of the underlying mechanism.
ME/CFS with MCAS (the situation this series is about). When MCAS sits on top of ME/CFS, three things are different:
- MCAS is usually later-arriving. It was typically detected after ME/CFS began, and it may be a downstream amplifier (see the caveats about detection-order above) (Rohrhofer et al. 2025).
- Treating mast cells treats one contributor. If an antihistamine calms your flushing or orthostatic symptoms, the honest reading is that histamine signalling was contributing to those symptoms — it does not by itself prove mast cells were the driver, and it does not mean the fatigue or the energy failure are fixed (Castells et al. 2024).
- A failed mast-cell trial says nothing against your ME/CFS. Because mast cells are only one of several possible routes in ME/CFS, and because one drug blocks only some of the chemicals involved, a drug that doesn’t help is a clue about one medication in one pathway — not a verdict on whether your illness is real.
Why this distinction matters practically: in ME/CFS, a mast-cell treatment is best thought of as a timed trial aimed at one possible contributor — with a clear idea of which symptoms it’s meant to touch, and a plan for what a partial or null result does or doesn’t mean — rather than as a test of whether mast cells “cause” your ME/CFS. An individual’s response tells you at most about that person’s symptoms, not about the amplifier-vs-bystander question in general — that needs a controlled trial. And the honest standing, given the data, is: if the amplifier model is right, calming mast cells may be worth doing — but that “if” is not yet settled, and a null result is entirely possible.
8 The threshold dropped: urticaria, then food, then dust — the allergy that spreads
People with MCAS often describe the same story, in the same order. It starts with one thing. Then the list grows.
Many describe it as starting in the skin: unexplained hives, flushing, an itch that comes and goes for no reason. Then foods start to cause trouble — the symptoms multiply, and the list of things you “can’t eat” grows. And later, for the most severe, even seemingly trivial things set off a reaction — a fabric, a fragrance, a light touch. (A word of caution on dust in particular: house dust does actually contain dust-mite allergen, the most common indoor trigger, so a dust reaction can be plain classical allergy — it’s the reactions to things with no known allergen, like a fragrance or temperature change, that point to the non-allergen pathways.)
This is not simply a growing number of separate allergies. A true food allergy means the immune system has made a specific antibody to one specific protein. If you were reacting to each food separately, you’d expect a slow accumulation of new allergies over years. MCAS feels different: a threshold that seems to drop, so that a small stimulus that used to be harmless becomes enough (Molderings et al. 2011). But be fair — there are alternative explanations for a growing list of triggers, not only a dropped threshold: dietary/gut histamine overload, anxiety- or expectancy-amplified attention to internal sensations, and the documented loss of tolerance that follows strict elimination diets. Patients and clinicians often hear the “threshold drop,” but the sequence alone can’t prove which is happening.
What plausibly drives the drop. Several documented mechanisms can make mast cells fire more easily and more loudly:
- Amplification by proximity. Mast cells physically clamp onto sensory nerve endings, and that contact amplifies their response — degranulation and inflammatory-signal release rises several-fold on direct contact (a cell-culture finding from a single study) (Magadmi et al. 2019). A separate idea — that repeated firing makes the whole circuit permanently more sensitive — is plausible and often invoked, but it is not what that study shows and is really a conjecture. Keep the two distinct: contact amplifies (better supported); past history permanently sensitises (a hypothesis).
- Nerve-driven alarm. Sensory nerves release substance P, which activates mast cells through the non-allergen MRGPRX2 pathway, and the two talk to one another — a given activation can transiently boost the other’s output (acute amplification within an episode, consistent with the contact effect above, not proof of lasting sensitisation) [Thapaliya et al. (2022)](Roy et al. 2021). Touch, movement, and odours are nerve events; once a nerve-mast cell conversation is running hot, ordinary contact can become enough to trigger a reaction in the moment.
- A shared energy failing — a hypothesis, not an established link. Mast cells, like muscle cells, need a careful balance of sodium and calcium to behave normally. If the cell’s sodium-potassium pump is impaired — a mechanism proposed for the muscle problems in ME/CFS — calcium could, in principle, flood into mast cells as well as muscle, so PEM and MCAS flares might turn out to be two symptoms of one shared cellular defect. This is developed in the primary document underlying this series; it is untested in patients, and it must be weighed against the more parsimonious null — that PEM and MCAS simply co-occur as parallel downstream consequences of illness severity or reduced activity, with no shared cellular flaw. The data do not currently separate these (Castells et al. 2024).
- More mediators, not just histamine. Mast cells fire a cocktail — histamine, prostaglandins, leukotrienes, tryptase, and more — and each acts on different tissue (Molderings et al. 2016). A full storm can reach the blood vessels, gut, lungs, and even reduce blood flow to the brain (Novak et al. 2022). The more mediators spill everywhere, the more systems a single trigger can disturb at once.
Honesty about the trajectory. The acute mechanisms — nerve-mast cell amplification within an episode, MRGPRX2 activation, the non-histamine mediators — are documented in the lab and in reviews. The permanent re-wiring idea (cumulative sensitisation, “priming” in the sense of lasting threshold change) is a plausible but unproven hypothesis, as noted above. The shared calcium-pump story is a genuine hypothesis: mechanistically coherent, but untested in patients so far, and it is developed in the primary document underlying this series rather than established in the literature. And the specific narrative of “urticaria, then foods, then near-anything, in that order” is what many patients and MCAS clinicians report, but it is an unsystematic clinical anecdote at this point: it has not been measured as a fixed sequence in a large prospective study. A skeptic would add that expanding trigger lists also arise from attention and avoidance-learning. So some of the handle is well-evidenced and some is hypothesis; the stomping rhythm a given patient describes is individual (Castells et al. 2024). Both can be true — the first is something we can cite, the second is how it shows up in a life.
9 The bottom line
MCAS is real and a meaningful subset of people with ME/CFS carry it (Rohrhofer et al. 2025). The honest read of the data is that it is most often later-arriving — detected after ME/CFS begins — which cools any “hidden cause” story, though detection-order limits mean even that is provisional. Whether it then worsens the illness (an amplifier) or largely co-exists with it (a bystander) is not yet settled by the evidence; separating the two would require a controlled trial showing improvement on core ME/CFS outcomes, not relief of mast-cell symptoms alone. The MCAS-alone vs ME/CFS-with-MCAS distinction matters because the treatment goal differs, but it is a clinical distinction, not a hard biological wall. Treating mast cells is reasonable to try as part of the picture; keeping both the “amplifier” and “bystander” readings open is what keeps this honest.
Next in this mini-series: how the actual medications work — the difference between H1 and H2 antihistamines, why your doctor raises the dose, and the mast-cell stabilisers see the companion article on treatment. And when the drugs don’t work, what that does and doesn’t tell you companion article on treatment failure.
For the comprehensive, fully-cited picture of how mast cells are weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).